ASIA

This region comprises all Asian territories where we sell products, including China. Active trading subsidiaries include those in China, the Philippines, Taiwan and Malaysia with other countries in the region reached via distributors. Sterile Focus Brands are the key contributor to revenue. Our manufacturing facility in India is our primary new product development site.

Key Countries

China
Malaysia
Philippines
Singapore
Taiwan

KEY COUNTRIES AND TERRITORIES

Brand		Therapeutic category
Diprivan		General anaesthetic
Eltroxin		Thyroid hormone replacement
Fraxiparine		Low molecular weight heparin
Ultiva		General anaesthetic
Xylocaine		Regional anaesthetic

NUMBER OF PERMANENT EMPLOYEES

1 214

June 2021

1 157

June 2020

STATISTICS

Number of products launched:

3

(2020: 1)

Number of product recalls:

Nil

(2020: Nil)

Average staff turnover:

24%

(2020: 30%)

Number of work-related fatalities:

Nil

(2020: Nil)

Sales representatives:

574

(2020: 598)

Revenue	2021 R’million	2020 (CER) R’million	Change %
Total Commercial Pharmaceuticals	5 117	4 457	15
Regional Brands	626	604	4
Sterile Focus Brands	4 491	3 853	17
Manufacturing – API Chemicals	77	113	(32)
Total	5 194	4 570	14

Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture.

The Chinese general anaesthesia therapy area consists of inhalation and intravenous products. The propofol market grew 10,6% year-on-year MAT* May 2021.
The South Korean pharmaceutical market is forecast to grow at a CAGR of 6% between 2019 and 2024, reaching Won24,579 billion by 2024.

Source: China IMS CHPA Report, May 2021.
*MAT = Moving annual total